Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Omeprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 6/20 | 0.59 |
| ▸ | ATP4B known ✓ | P51164 | 6/20 | 0.59 |
| ▸ | BRS3 | P32247 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.59 |
| ▸ | ATP1A1 | P05023 | 5/20 | 0.59 |
| ▸ | ATP1B1 | P05026 | 5/20 | 0.59 |
| ▸ | ATP1A3 | P13637 | 5/20 | 0.59 |
| ▸ | ATP1B2 | P14415 | 5/20 | 0.59 |
| ▸ | ATP1A2 | P50993 | 5/20 | 0.59 |
| ▸ | ATP1B3 | P54709 | 5/20 | 0.59 |
| ▸ | FXYD2 | P54710 | 5/20 | 0.59 |
| ▸ | ATP1A4 | Q13733 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.59 |
| ▸ | WDR5 | P61964 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.59 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Esomeprazole SCHEMBL19535 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL28256108 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL29691369 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL29772327 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL140006 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL1192 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL30426884 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL29360040 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL589808 | 0.98 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL2516731 | 0.98 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1595879-A2 | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same | aaiPharma Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1206466-B1 | ALKOXY SUBSTITUTED BENZIMIDAZOLE COMPOUNDS, PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | AAIPHARMA INC (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20040157887-A1 | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same | WELLS FARGO BANK, N.A. | 2004-08-12 | — | — | US | disclosed |
| US-6706737-B2 | INHIBITING GASTRIC ACID SECRETION ARE KNOWN IN THE ART AND INCLUDE A CLASS OF BENZIMIDAZOLE- SUBSTITUTED COMPOUNDS, ONE OF WHICH IS OMEPRAZOLE | AAIPHARMA SERVICES CORP. | 2004-03-16 | — | — | US | disclosed |
| US-6667321-B2 | Used in inhibiting gastric acid secretion | REGIONS BANK | 2003-12-23 | — | — | US | disclosed |
| US-6667324-B1 | Omeprazole with its positional isomer and diastereomers; gastric acid related diseases | REGIONS BANK | 2003-12-23 | — | — | US | disclosed |
| US-6667323-B1 | Omeprazole with its positional isomer and diastereomers | REGIONS BANK | 2003-12-23 | — | — | US | disclosed |
| US-20030225136-A1 | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same | AAIPHARMA SERVICES CORP. | 2003-12-04 | — | — | US | disclosed |
| US-20030225135-A1 | DRY-BLEND PHARMACEUTICAL FORMULATIONS | AAIPHARMA SERVICES CORP. | 2003-12-04 | — | — | US | disclosed |
| US-20030225137-A1 | DRY BLEND PHARMACEUTICAL FORMULATIONS | AAIPHARMA SERVICES CORP. | 2003-12-04 | — | — | US | disclosed |
| EP-1206466-A1 | ALKOXY SUBSTITUTED BENZIMIDAZOLE COMPOUNDS, PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | aaiPharma Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| US-6369087-B1 | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same | ALCAMI CAROLINAS CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-6326384-B1 | CONTAINING 6-METHOXY-2-(((4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL)-SULF INYL)-1H-BENZIMIDAZOLE; ORAL ADMINISTERING | ALCAMI CAROLINAS CORPORATION | 2001-12-04 | — | — | US | disclosed |
| US-6316020-B1 | Pharmaceutical formulations | AAIPHARMA SERVICES CORP. | 2001-11-13 | — | — | US | disclosed |
| US-6312723-B1 | COMPOUNDS USED IN INHIBITING GASTRIC ACID SECRETION 6-METHOXY-2-(((4-METHOXY-3, 5-DIMETHYL-2-PYRIDINYL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE IN TABLET OR CAPSULE FORM WITH CYCLODEXTRIN | AAIPHARMA SERVICES CORP. | 2001-11-06 | — | — | US | disclosed |
| US-6312712-B1 | Method of improving bioavailability | AAIPHARMA SERVICES CORP. | 2001-11-06 | — | — | US | disclosed |
| US-6268385-B1 | 6-METHOXY-2-(((4-METHOXY-3, 5-DIMETHYL-2-PYRIDINYL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE; TREATING GASTRIC ACID RELATED DISEASES IN MAMMALS | REGIONS BANK | 2001-07-31 | — | — | US | disclosed |
| US-6262086-B1 | 6-METHOXY-2-(((4-METHOXY-3, 5-DIMETHYL-2-PYRIDINYL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE; ANTISECRETORY AGENTS | REGIONS BANK | 2001-07-17 | — | — | US | disclosed |
| US-6262085-B1 | TREATING GASTRIC ACID RELATED DISEASES IN MAMMALS | ALCAMI CAROLINAS CORPORATION | 2001-07-17 | — | — | US | disclosed |
| WO-2001014367-A1 | ALKOXY SUBSTITUTED BENZIMIDAZOLE COMPOUNDS, PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | APPLIED ANALYTICAL INDUSTRIES, INC. (US) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225137-A1 | DRY BLEND PHARMACEUTICAL FORMULATIONS | CYP2D6, CYP2C19, CYP2B6 | ATP4A 2699/4885ATP4B 1510/4885BRS3 563/4885 |
| US-20040157887-A1 | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same | CYP2C19, CYP3A5, CYP3A4 | ATP4A 1549/4885ATP4B 876/4885BRS3 695/4885 |
| US-20030225135-A1 | DRY-BLEND PHARMACEUTICAL FORMULATIONS | CYP2C19, CYP2D6, CYP2C9 | ATP4A 2784/4885ATP4B 1648/4885BRS3 615/4885 |
| US-20030225136-A1 | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same | CYP2C19, CYP3A5, CYP3A4 | ATP4A 1549/4885ATP4B 876/4885BRS3 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.